# Accustem Sciences Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Accustem Sciences Inc.). ## Overview Accustem Sciences Inc. is a clinical-stage diagnostics company focused on developing genomic tests for oncology decision-making. Its core programs are MSC (MicroRNA Signature Classifier) for patients with lung nodules and StemPrintER for early-stage breast cancer, with plans to expand the StemPrint platform into additional tumor types. The company is still in the development and commercialization-build phase and has not yet generated product revenue. It is working through laboratory transfer, CLIA certification, and reimbursement milestones before launching its tests commercially in the United States. ## Products & services • MSC (MicroRNA Signature Classifier) for lung nodules • StemPrintER for early-stage breast cancer • Ancillary testing: next-generation sequencing • Ancillary testing: IHC receptor status • Ancillary testing: hereditary gene panels • Future StemPrint assays for additional tumor types - **Oncology genomic classifiers** (70%) — Proprietary molecular tests intended to support cancer diagnosis and treatment decisions, including MSC and StemPrintER. - **Ancillary laboratory testing** (30%) — Commodity tests offered alongside the core classifiers to improve customer value and laboratory utilization. - MSC (MicroRNA Signature Classifier) for lung nodules - StemPrintER for early-stage breast cancer - Ancillary next-generation sequencing testing - IHC receptor status testing - Hereditary gene panel testing - StemPrint platform assays for additional tumor types ## Customers Accustem’s customers are expected to be clinicians and healthcare systems that need genomic information to guide oncology care. For MSC, the target use case is patients with lung nodules, where the test is intended to help determine clinical management and support reimbursement-backed adoption. For StemPrintER, the customer is the breast cancer care pathway, especially providers treating early-stage breast cancer who need risk stratification and decision support. The company also expects ancillary tests such as next-generation sequencing, IHC receptor status, and hereditary panels to be purchased as add-ons that increase the value of each case and improve laboratory economics. - **Lung nodule care providers** (primary) — Clinicians and institutions evaluating lung nodules who would use MSC to support diagnosis and management decisions. - **Early-stage breast cancer providers** (primary) — Oncology providers treating early-stage breast cancer who would use StemPrintER to inform care decisions. - **Ancillary test buyers** (secondary) — Customers purchasing add-on molecular tests such as next-generation sequencing, IHC receptor status, and hereditary panels. - **Partner laboratory channel** (secondary) — Commercial laboratory partners that process, test, and report results for commercial samples. - Oncologists treating patients with lung nodules who need risk stratification - Breast cancer clinicians using StemPrintER for early-stage treatment decisions - Hospitals and health systems seeking reimbursable molecular diagnostics - Reference laboratories and partner labs processing commercial samples - Patients whose care teams require genomic evidence to guide management ## Geography Accustem is headquartered and operates from New York, NY and London, UK, while substantially all of its assets are located in the United States. The company’s initial commercialization focus is the U.S. market, where it expects to launch MSC first and where it estimates a large addressable revenue opportunity. It has partnered with EmeritusDx in Lake Forest, California to support commercial laboratory processing. Management has also indicated that it may expand into other markets later, depending on clinical need and revenue opportunity. - **United States** (100%) — Initial commercialization focus and substantially all assets are in the U.S.; no revenue has been generated yet. - Headquarters and operations in New York, NY and London, UK - Substantially all assets located in the United States - Initial commercialization targeted at the U.S. market - Commercial lab partner located in Lake Forest, California - Potential future expansion into other markets after U.S. launch ## Strategy Accustem’s strategy is to move from clinical development into commercial launch by completing the operational milestones required for reimbursement-ready testing. The company is prioritizing laboratory transfer, commercial lab validation, and CLIA certification so that MSC can be reported for clinical use and billed to payers. It is also broadening the value proposition by bundling ancillary tests with its core assays, which should improve customer utility and laboratory economics. Longer term, management wants to extend the StemPrint platform beyond breast cancer into additional tumor types to widen the addressable market. - **Commercialize MSC in the U.S.** (short-term) — MSC needs clinical validation, laboratory transfer, and reimbursement readiness before it can generate revenue. - **Build reimbursement support** (short-term) — Peer-reviewed publications and payer acceptance are required for adoption and monetization of the genomic classifier. - **Expand the StemPrint platform** (medium-term) — Broader tumor-type coverage could increase the commercial opportunity beyond breast cancer. - Complete transfer of MSC into a U.S. commercial laboratory - Obtain CLIA certification to support clinical reporting and reimbursement - Launch MSC first in the United States before broader expansion - Use ancillary tests to increase per-case value and lab utilization - Validate StemPrint in additional tumor types beyond breast cancer ## Risks The company faces execution risk because it has no approved commercial products and must complete several technical and regulatory milestones before launch. Its ability to commercialize depends on successful laboratory transfer, CLIA certification, and payer reimbursement, any of which could be delayed or fail. As a diagnostics developer, it also faces scientific and clinical adoption risk: the tests must continue to demonstrate utility in real-world care and maintain support from physicians and payers. Financially, the business is exposed to funding risk because it has no revenue, no committed external capital, and ongoing losses, while internal control weaknesses and limited accounting resources add reporting and operational risk. - **Commercialization milestone delays** [high] — MSC and StemPrintER require lab transfer, validation, and CLIA certification before clinical launch. - **Reimbursement uncertainty** [high] — The company states that peer-reviewed publications and payer reimbursement are necessary for commercialization. - **Going-concern and financing dependence** [critical] — The company has no revenue, no committed external funding, and ongoing losses. - **Internal control weakness** [high] — Management disclosed ineffective controls due to lack of accounting resources and inadequate segregation of duties. - No commercial revenue yet, so the business depends on successful launch execution - CLIA certification and lab transfer could delay commercialization - Reimbursement risk if CMS and other payers do not accept the tests - Clinical adoption risk if physicians do not view the tests as sufficiently useful - Funding risk because operations are financed through external capital raises - Internal control weaknesses due to limited accounting resources - Potential dependence on partner laboratory performance and availability ## Accounting Accustem currently reports no product revenue, so the main accounting focus is on operating expenses, capital raising, and the timing of development costs. Research and development spending can fluctuate materially quarter to quarter based on laboratory work, consulting, and patent-related activity, which makes interim comparisons noisy. The company also disclosed a material weakness in internal control over financial reporting due to inadequate accounting resources and segregation of duties, which increases the risk of misstatement in the financial statements. Because the business is pre-revenue and loss-making, investors should also watch how management classifies and discloses development-stage costs, stock-based compensation, and any future commercialization-related revenue recognition once testing begins. - **Material weakness in internal controls** — Raises the risk of financial statement error and delayed reporting - **R&D expense volatility** — Makes operating loss trends less comparable across periods - **Pre-revenue accounting** — Financial statements are dominated by expense recognition and financing activity - No revenue recognized yet, so results are driven by operating expenses - R&D expense can swing with lab work, consulting, and patent activity - General and administrative costs are sensitive to headcount and payroll - Material weakness in internal controls raises reporting reliability risk - Future revenue recognition will depend on how testing services are contracted and billed - Pre-revenue stage increases reliance on estimates and judgment in expense classification --- *Last updated: 2026-08-11T04:46:19.379856+00:00*